Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-PEGylated disarylbisthiazoles
- Development stage
- Preclinical
- Lead developer
- Philipps-Universität Marburg
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-PEGylated disarylbisthiazoles (DABTAs) are a class of fluorine-18 labeled, PEGylated diarylbisthiazole-based radiotracers developed for positron emission tomography (PET) imaging of alpha-synuclein (α-syn) aggregates. Developed by researchers at Philipps University Marburg, Uppsala University, and the Technical University of Munich, these compounds are designed to selectively bind to α-syn fibrils with high affinity while demonstrating excellent selectivity over amyloid-beta (Aβ) and tau aggregates. PEGylation of the DABTA scaffold is utilized to optimize the pharmacokinetics and lipophilicity (logD) of the tracers, improving brain uptake and washout characteristics for the early diagnosis of α-synucleinopathies, such as Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies.
- Other names
- 18F-PEGylated DABTAsPEGylated 18F-DABTAsPEGylated18F-DABTAsPEGylated-18F-DABTAsPEGylated 18F-disarylbisthiazolesPEGylated18F-disarylbisthiazolesPEGylated-18F-disarylbisthiazoles
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on 18F-PEGylated disarylbisthiazoles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-PEGylated disarylbisthiazoles.